Ann: FDA Grants PharmAust Pre-IND Meeting, page-35

We have had some encouraging interim biomarker results and positive and bullish messaging from the company, fda ODD application, phase 2/3 trial planned for 2H 24 with possible fast track approval, we’ve heard that some of the trial patients have also become shareholders but we have nothing solid re clinical benefits from the principal investigator to backup these interim results. There are high expectations and unless the phase1/2 results live up to the hype there could be some disappointment. We won’t hear if FightMND come onboard with funding for the phase 2/3 trial until later in the year also. Everything is pointing to positive outcomes but we need to get some solid phase1/2 results to get some score on the board IMO. There seems to be a lot of grey in the information about life expectancy and disease progression with this disease so it will great to get some solid news on how MPL is going.